Mandai Koichiro, Shirakawa Atsushi, Uno Koji, Yasuda Kenjiro
Department of Gastroenterology, Kyoto Second Red Cross Hospital, Kyoto, Japan.
Case Rep Oncol. 2017 Jan 9;10(1):15-20. doi: 10.1159/000455226. eCollection 2017 Jan-Apr.
Gastrointestinal perforation is a serious adverse event that occurs in approximately 1% of patients receiving ramucirumab and paclitaxel. A 67-year-old man with unresectable advanced gastric cancer was admitted to our hospital and treated with ramucirumab and paclitaxel. Gastric perforation occurred during the second cycle of chemotherapy. Although the patient's condition improved without surgery, an abscess developed in the intra-abdominal fluid collection resulting from the perforation. We performed endoscopic ultrasound-guided abscess drainage. The patient improved and was discharged in satisfactory condition. Endoscopic ultrasound-guided drainage is a treatment option for patients with intra-abdominal abscess following gastric perforation due to ramucirumab.
胃肠道穿孔是一种严重的不良事件，在接受雷莫西尤单抗和紫杉醇治疗的患者中发生率约为1%。一名67岁的不可切除晚期胃癌男性患者入住我院，接受雷莫西尤单抗和紫杉醇治疗。化疗第二周期期间发生胃穿孔。尽管患者未经手术病情有所改善，但穿孔导致的腹腔积液中形成了脓肿。我们进行了内镜超声引导下脓肿引流。患者病情好转，出院时情况良好。内镜超声引导下引流是雷莫西尤单抗所致胃穿孔后腹腔脓肿患者的一种治疗选择。
